Mavorixafor hydrochloride  (Synonyms: AMD-070 hydrochloride)

Mavorixafor (AMD-070) hydrochloride is a potent, selective and orally available CXCR4 antagonist, with an IC₅₀ value of 13 nM against CXCR4 ¹²⁵I-SDF binding. Mavorixafor hydrochloride also inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs with an IC₅₀ of 1 nM and 9 nM, respectively^[1].

Mavorixafor (AMD-070) hydrochloride 对其他趋化因子受体（CCR1、CCR2b、CCR4、CCR5、CXCR1 和 CXCR2）没有影响^[1]。 Mavorixafor（6.6 µM；14-21 天）hydrochloride 显着抑制 B88-SDF-1 细胞的贴壁依赖性生长。Mavorixafor hydrochloride 显着损害 B88-SDF-1 细胞增强的运动性。Mavorixafor hydrochloride 还显着抑制 B88-SDF-1 细胞的迁移和 Matrigel 侵袭^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Mavorixafor (2 mg/kg；口服；每天一次；持续 49 天) hydrochloride 显着抑制裸鼠 B88-SDF-1 细胞的肺转移^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

385.93

C₂₁H₂₈ClN₅

880549-30-4

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Skerlj RT, et al. Discovery of novel small molecule orally bioavailable C-X-C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication. J Med Chem. 2010 Apr 22;53(8):3376-88.  [Content Brief]

  [2]. Uchida D, et al. Effect of a novel orally bioavailable CXCR4 inhibitor, AMD070, on the metastasis of oral cancer cells. Oncol Rep. 2018 Jul;40(1):303-308.  [Content Brief]